
Collagen inhibitors - Pipeline Insight, 2024
Description
Collagen inhibitors - Pipeline Insight, 2024
DelveInsight’s, “Collagen inhibitors - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Collagen inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Collagen inhibitors: Overview
Collagen is an essential part of the framework of the design of our various body tissues. It is the major insoluble fibrous protein in the extracellular matrix and in connective tissue.
Function –Collagen is a member of a family of naturally occurring proteins. It is one of the most plentiful proteins present in mammals and it is responsible for performing a variety of important biological functions. It is most well-known for the structural role it plays in the body. It is present in large quantities in connective tissue and provides tendons and ligaments with tensile strength and skin with elasticity. It often works in conjuction with other important proteins such as keratin and elastin.
Collagen inhibitors- Inhibition of collagen formation is an attractive target to reduce excessive formation of fibrotic tissue. Unlike canonical inhibitors of excessive accumulation of collagen-rich deposits, inhibition of collagen fibril formation targets a specific, extracellular event. Blocking collagen fibril formation may serve as an independent or supporting method to reduce excessive, localized accumulation of collagen-rich deposits.Antibody-based inhibitors of collagen fibril formation are promising therapeutic agents with a potential to limit localized fibrosis in a number of tissues.
Collagen inhibitors Emerging Drugs Chapters
This segment of the Collagen inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Collagen inhibitors Emerging Drugs
- Remlarsen: miRagen Therapeutics
- Hydronidone: Shanghai Genomics
Further product details are provided in the report……..
Collagen inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Collagen inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Collagen inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Collagen inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Collagen inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Collagen inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Collagen inhibitors R&D. The therapies under development are focused on novel approaches for Collagen inhibitors.
- Collagen inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Collagen inhibitors drugs?
- How many Collagen inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Collagen inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Collagen inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Collagen inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- miRagen Therapeutics
- Shanghai Genomics
- Matrizyme
- Roche
- NeuMedics
- Processa Pharmaceuticals
- Remlarsen
- Hydronidone
- MZ-004
- Pirfenidone
- NM 108
- Halofuginone
Table of Contents
50 Pages
- Introduction
- Executive Summary
- Collagen inhibitors: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Collagen inhibitors – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Collagen inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Collagen inhibitors Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Pre-registration)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Remlarsen : miRagen Therapeutics
- Product Description
- Research and Development
- Comparative Analysis
- Hydronidone : Shanghai Genomics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Collagen inhibitors Key Companies
- Collagen inhibitors Key Products
- Collagen inhibitors- Unmet Needs
- Collagen inhibitors- Market Drivers and Barriers
- Collagen inhibitors- Future Perspectives and Conclusion
- Collagen inhibitors Analyst Views
- Collagen inhibitors Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.